Bambusa Therapeutics, Inc. Form S-1 — Oct 9, 2026
Bambusa Therapeutics, a clinical-stage biopharmaceutical company developing long-acting bispecific antibodies for immunology and inflammation, filed an S-1 for its IPO on Nasdaq under the proposed symbol BBTX, with BofA Securities, Evercore ISI, UBS Investment Bank, and Cantor as underwriters. Pricing terms, share count, and proceeds are not yet disclosed in this preliminary prospectus. Lead candidate BBT001, targeting IL-4Rα and IL-31, showed positive proof-of-concept data in moderate-to-severe atopic dermatitis in July 2026, with 82% EASI-50 and 64% EASI-50+ placebo-adjusted response at Week 6, and no conjunctivitis cases reported.
Key figures
- Total Debt
- 12223000
- Total Assets
- 77496000
- Shares Outstanding
- 25740828
- Employees
- 30
- Fy2025 net loss
- $41.1 million
- Working capital
- $63.1 million
- H1 2026 net loss
- $22.4 million (vs $14.7 million prior-year period)
- H1 2026 rd expense
- $20.6 million
- Accumulated deficit
- $77.2 million as of June 30, 2026
- Gross private financing raised
- $136.1 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.